haematology
Blood cancers

CAR-T therapy gets TGA approval for ALL and DLBCL


CAR-T therapy tisagenlecleucel (formerly CTL019) has been approved by the TGA for use in paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL). The therapy – marketed as Kymriah by Novartis...

CAR-T therapy tisagenlecleucel (formerly CTL019) has been approved by the TGA for use in paediatric and young adult patients up...

Read more